ccostr: An R package for estimating mean costs with censored data

Børty, Lars; Brøndum, Rasmus Froberg; Bøgsted, Martin

doi:10.21105/joss.01593

Cited by 4 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who were still attending the pediatric rheumatology clinic by the end of the study observation period, moved to another province, or were lost to follow-up were considered right censored in the analysis. To account for censoring in the healthcare cost estimates, we used the Zhao and Tian estimator (or weighted available sample estimator) for censored data with cost history [ 26 ]. The total cumulative mean cost including 95% confidence intervals was calculated for overall and JIA-associated costs for a period of 6 years.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study

et al. 2021

View full text Add to dashboard Cite

Introduction: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease, whose multifaceted care path can lead to significant expenditure for the healthcare system. We aim to assess the real-world healthcare resource use (HCRU) and associated cost for children with JIA in a single center in Canada. Methods: A single-center consecutive cohort of newly diagnosed patients with JIA attending the pediatric rheumatology clinic from 2011 to 2019 was identified using an administrative

show abstract

Section: Methodsmentioning

confidence: 99%

“…The cumulative mean costs using the Zhao and Tian estimator are calculated by weighting the costs of the whole available sample, including censored cases, and partitioning the time over the observation period. The Zhao and Tian estimator has been shown to be more accurate than other estimators when cost history is available [ 26 , 27 ].…”

Section: Methodsmentioning

confidence: 99%

Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…All analyses were run using R version 3.6.0. In particular, the package survival was used for Cox regression model (Therneau & Lumley, 2015) and cmprsk for competing risk (Gray & Gray, 2020), ipw for inverse probability of treatment weighting (van der Wal et al, 2011), MatchIt for propensity score matching (Ho, 2027) and ccostr for Kaplan-Meier sample average (Børty, Brøndum, & Bøgsted, 2019).…”

Section: Kaplan-meier Sample Averagementioning

confidence: 99%

How real can we get in generating real world evidence? Exploring the opportunities of routinely collected administrative data for evaluation of medical devices

Pongiglione

Torbica

2022

Health Economics

View full text Add to dashboard Cite

Real‐world data are considered a potentially valuable source of evidence for assessing medical technologies in clinical practice, but their widespread use is hampered by numerous challenges. Using the case of coronary stents in Italy, we investigate the potential of administrative databases for estimating costs and health outcomes associated with the use of medical devices in real world conditions. An administrative dataset was created ad hoc by merging hospital records from patients admitted between 2013 and 2019 for stent implantations with ambulatory records, pharmaceutical use data and vital statistics. Health outcomes were multifold: all‐cause and cardiac mortality and myocardial infarction, within 30 days, 1, 2, 5 years. Costs were estimated from the National Health System perspective. We used multivariable Cox models and propensity score (PS) methods (PS matching; stratification on PS; inverse probability of treatment weighting using PS; PS adjustment). 257,907 coronary stents were implanted in 113,912 patients. For all health outcomes and follow‐up times, and across all methods, patients receiving drug‐eluting stents (DES) presented lower risk. For all‐cause mortality, the DES patient advantage over bare‐metal stent (BMS) patients declined over time but remained significant even at 5 years. For myocardial infarction, results remained quite stable. The DES group presented lower cumulative total costs (ranging from 3264 to 2363 Euros less depending on methods). Our results confirm the consolidated evidence of the benefits of DES compared to BMS. The consistency of results across methods suggests internal validity of the study, while highlighting strengths and limitations of each depending on research context. Administrative data yield great potential to perform comparative effectiveness and cost‐effectiveness analysis of medical devices provided certain conditions are met.

show abstract

“…The package ccostr [39] was used in RStudio (RStudio Team (2021), version 1.4.1103) for estimation of costs for the average sample (mean total cost, AS) (base-case) and Zhao and Tian estimator. Incremental cost-effectiveness ratios (ICERs) were calculated for all treatment lines and the combined sequences.…”

Section: Costsmentioning

confidence: 99%

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Pereira-Salgado

Antón

Franchini

et al. 2022

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction:Health economic outcomes of real-world treatment sequencing of androgen receptortargeted agents (ARTA) and docetaxel (DOC) remain unclear. Material and Methods: Data from the electronic Castration-resistant Prostate cancer Australian Database (ePAD) were analyzed including median overall survival (mOS) and median time-totreatment failure (mTTF). Mean total costs (mTC) and incremental cost-effectiveness ratios (ICER) of treatment sequences were estimated using the average sample method and Zhao and Tian estimator. Results: Of 752 men, 441 received ARTA, 194 DOC, and 175 both sequentially. Of participants treated with both, first-line DOC followed by ARTA was the more common sequence (n = 125, 71%). mOS for first-line ARTA was 8.38 years (95% CI: 3.48, not-estimated) vs. 3.29 years (95% CI: 2.92, 4.02) for DOC. mTTF was 15.7 months (95% CI: 14.2, 23.7) for the ARTA-DOC sequence and 18.2 months (95% CI: 16.2, 23.2) for DOC-ARTA. In first-line, ARTA cost an additional $13,244 per mTTF month compared to DOC. In second-line, ARTA cost $6726 per mTTF month. The DOC-ARTA sequence saved $2139 per mTTF compared to ARTA-DOC, though not statistically significant. Conclusion: ICERs show ARTA had improved clinical benefit compared to DOC but at higher cost. There were no significant cost differences between combined sequences.

show abstract

ccostr: An R package for estimating mean costs with censored data

Cited by 4 publications

References 7 publications

Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study

Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study

How real can we get in generating real world evidence? Exploring the opportunities of routinely collected administrative data for evaluation of medical devices

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Contact Info

Product

Resources

About